The Value of Knowing: CMS Rejects Coverage of Lilly’s Amyvid – Except As Tool For Further Research
This article was originally published in RPM Report
Executive Summary
CMS is proposing to deny coverage of Lilly’s Alzheimer’s “rule-out” diagnostic Amyvid. The decision is important for biopharma manufacturers for several reasons, both as a demonstration that the agency really will refuse to pay for FDA approved drugs—and for how CMS thinks it can actually use its authority to encourage research on effective AD therapies.
You may also be interested in...
CMS Sticks To Its Guns: Amyvid Alzheimer’s Screening Not Covered In Medicare Population
The final coverage decision for Lilly’s Amyvid sticks with the proposal to limit payment to use in clinical trials. That is a setback for Lilly, but reinforces the Medicare agency’s commitment to the Coverage with Evidence Development pathway.
Imaging Groups Disappointed By CMS’ Final Beta Amyloid PET NCD
Agency’s final national coverage determination for beta amyloid positron emission tomography to diagnose dementia confirms that Medicare will cover the procedure only in clinical trials. On the positive side, it may offer a bit more flexibility in trial design.
CMS’ Amyvid Final NCD Clarifies Trial Outcomes Goals
Agency’s final national coverage determination for beta amyloid positron emission tomography in diagnosing dementia confirms stance the diagnostic will be covered only in trial setting for Medicare, but may offer a little more flexibility in trial design.